Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Núria PlanellCentro de Investigación Médica Aplicada (CIMA), Computational Biology Program, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad de Navarra, Pamplona, Spain.ORCID 0000-0001-7550-2433
Xabier Martínez-de-MorentinTranslational Bioinformatics Unit, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra (UPNA), Pamplona, Spain.ORCID 0000-0002-8358-9214
Daniel MouzoTranslational Bioinformatics Unit, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra (UPNA), Pamplona, Spain.ORCID 0000-0002-0383-5703
David Lara-AstiasoHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.
Amaia Vilas-ZornozaHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.
Patxi San Martín-UrizHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.ORCID 0000-0003-1483-4279
Diego AlignaniFlow Cytometry Core Facility, Centro de Investigación Médica Aplicada, CCUN, IdiSNA, CIBERONC, Universidad de Navarra, Pamplona, Spain.ORCID 0000-0003-0241-1375
Bruno PaivaClínica Universidad de Navarra, Centro de Investigación Médica Aplicada, CCUN, IdiSNA, CIBERONC, Universidad de Navarra, Pamplona, Spain.ORCID 0000-0003-1977-3815
Alberto MailloBioscience Program, Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology KAUST, Thuwal 23955, Saudi Arabia.ORCID 0000-0002-3835-9794
Aleksandra KurowskaBioscience Program, Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology KAUST, Thuwal 23955, Saudi Arabia.
Nerea BerasteguiHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.ORCID 0000-0002-9868-0547
Paula Garcia-OlloquiHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.ORCID 0000-0002-7983-2875
Arantxa UrdangarinTranslational Bioinformatics Unit, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
Peri NooriTranslational Cardiology, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
Asier Ortega-LegarretaTranslational Bioinformatics Unit, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra (UPNA), Pamplona, Spain.ORCID 0009-0000-3563-5362
Mikel HernaezCentro de Investigación Médica Aplicada (CIMA), Computational Biology Program, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad de Navarra, Pamplona, Spain.ORCID 0000-0003-0443-2305
Vincenzo LaganiBioscience Program, Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology KAUST, Thuwal 23955, Saudi Arabia.ORCID 0000-0002-6552-6076
Narsis KianiDepartment of Oncology-Pathology, Center of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-0949-046X
Matthias MerkenschlagerMRC LMS, Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.ORCID 0000-0003-2889-3288
Teresa EzpondaHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.ORCID 0000-0003-3682-7125
José I Martín-SuberoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona.ORCID 0000-0001-8809-5195
Ricardo N RamírezDepartment of Immunology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-1259-5406
Jesper TegnerComputer, Electrical, and Mathematical Sciences and Engineering Division (CEMSE), King Abdullah University of Science and Technology KAUST, Thuwal 23955, Saudi Arabia.ORCID 0000-0002-9568-5588
Felipe ProsperHematology-Oncology Program, CIMA, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.ORCID 0000-0001-6115-8790
David Gomez-CabreroTranslational Bioinformatics Unit, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra (UPNA), Pamplona, Spain.ORCID 0000-0003-4186-3788
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Dysregulation of early B cell lymphopoiesis-the process guiding cellular immunity development-can lead to malignancy, making it crucial to understand its regulatory mechanisms. We generated a multiomics resource comprising paired chromatin accessibility and gene expression profiles across eight human B cell precursor populations, providing a detailed characterization of early human B cell development. Integrative analysis revealed highly cell type-specific regulatory elements and enabled the reconstruction of the gene regulatory network governing differentiation. We identified putative candidate regulons, such as ELK3, enriched in pro-B cells and potentially involved in cell cycle progression. Regulons from bulk data were projected onto single-cell data, validating their activity and refining the regulatory landscape. This resource enabled identification of active regulatory programs and transformation-associated states in B cell acute lymphoblastic leukemia. The publicly available atlas provides a valuable resource for understanding B cell development and disease, supporting future efforts to decode regulatory programs in immunity and hematologic malignancies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Uncovering the regulatory landscape of early human B cell lymphopoiesis and its implications in the pathogenesis of B-ALL. · full record | OpenQuestion